Cipla Ltd Q4 FY2022 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/ylxj0pqxeinijmeh97aywmzb.pdf

Key Takeaways


India Business: The Growth Engine

Vohra: "We are quite clear, I think we would like to see very high growth, better than market for the non-COVID portfolio. And I think our business momentum is very strong across all the 3 businesses."

U.S. Business: Respiratory & Complex Generics Pipeline

Vohra: "We have overachieved what we thought we could do with albuterol, which was again a market category where we were launching as probably the third or the fourth variant of albuterol in this market. ... we've consistently tried to gain share there. So, I think those share conversions happen. It's a matter of time. And we're quite bullish about it."

Margins: One-Time Hits Mask Underlying Expansion


SAGA & International Markets: Steady Amid Volatility


Capital Allocation: Cash-Rich and Hunting in India

Vohra: "I'm happy that we are in this situation because 2 years back, we were a net debt company. So, with our strong cash flow generation, today we have reached a point where we have Rs. 4,000 crore of cash."

Guidance & Commitments

CommitmentSpecificsTimeline
India non-COVID growthGrow "very high," better than market across all three businessesFY23
Operating marginUpwards of 21%, in the 21% to 22% range, factoring in high commodity and procurement inflationFY23
Operating margin without AdvairCan still deliver 21%+ even if Advair does not launch this yearFY23
R&D expenseBetween 6% and 7% of salesFY23
Advair launchHoping for launch, pending facility inspectionH2FY23
Abraxane launchHoping for launch, pending FDA auditH2FY23
Generic Revlimid launchIn the second-half launch wave for strengths where exclusivity endsH2FY23
Peptide injectable filingOne peptide injectable to be filedFY23
India consumer healthGrow sustainably from EBITDA breakevenFY23
Complex generics filingsFilings in complex generics, including peptide injectables, shall continueFY23

Key Metrics

MetricQ4 FY22
Revenue₹5,260 cr, +14% YoY
Core revenue growth (ex-COVID)12% YoY for the quarter and full year
Reported gross margin59.2%, includes ~300 bps impact from COVID inventory charge
Reported EBITDA₹763 cr, 14.5% of sales
Adjusted EBITDA (ex-one-time charges)₹960 cr, 18%+ margin, +100 bps YoY
Adjusted EBITDA margin guidance (FY23)21% to 22% range
Reported PAT₹362 cr, 6.9% of sales
Adjusted PAT (ex-one-off items)~₹610 cr, 11% of sales
Effective tax rate (quarter)15.9%; full year ETR 26.7%
R&D spend6.1% of sales, ₹322 cr
One-India business growth21% YoY; 15% adjusted for COVID portfolio
India consumer health revenue (FY22)Crossed ₹500 cr, achieved EBITDA breakeven in FY22
U.S. core formulation sales$160 mn, multi-quarter high
U.S. full year revenue$594 mn
U.S. respiratory franchise growth21% QoQ, 28% for full year
SAGA region growth8% YoY in dollar terms
South Africa private business growth17% YoY in local currency
South Africa market share7.5%, third position
International markets revenue (full year)$385 mn, +4% YoY for the quarter
Pretax return on invested capitalOver 21.6%
Net cash positionNet cash positive as of March 2022
Cash on balance sheet₹4,000 cr
One-time charges₹200 cr: ₹160 cr COVID inventory charge, ₹20 cr COVID opex, ₹20 cr South Africa restructuring
Sri Lanka FOREX loss₹42 cr on outstanding receivables
Impairment charge (Avenue investment)~₹70 cr
Albuterol market share~22%
Freight and procurement cost impact~50 to 70 bps broadly on full-year basis
U.S. incremental revenue opportunity by FY25$300 mn to $500 mn, from organic pipeline